Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …

Colorectal cancer is a leading cause of cancer related deaths worldwide. One of the
hallmarks of cancer and a fundamental trait of virtually all gastrointestinal cancers is …

Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery
can identify patients with minimal residual disease (MRD) who will ultimately recur. Most …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Background In patients with resectable colorectal liver metastases (CRLM), the role of pre-
and postoperative systemic therapy continues to be debated. Previous studies have shown …

Background Precise methods for postoperative risk stratification to guide the administration
of adjuvant chemotherapy (ACT) in localized colorectal cancer (CRC) are still lacking. Here …

Background For locally advanced rectal cancer (LARC) patients who receive neoadjuvant
chemoradiotherapy (nCRT), there are no reliable indicators to accurately predict …

Purpose: We investigated the value of circulating tumor DNA (ctDNA) in predicting tumor
response to neoadjuvant chemoradiotherapy (nCRT), monitoring tumor burden, and …

Studies in multiple solid tumor types have demonstrated the prognostic significance of
ctDNA analysis after curative intent surgery. A combined analysis of data across completed …

Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of
malignancy. Although the cancer has been treated in these patients, the benefits of …